New Insights into Alzheimer's Disease: Glutaminyl Cyclase as a Promising Drug Target

A study has shed new light on the development of Alzheimer's disease (AD), with researchers at Virginia Commonwealth University identifying glutaminyl cyclase (QC) as a potential drug target. This discovery offers a promising therapeutic strategy against AD, which has become a pressing concern for the aging population. Current AD treatments mainly focus on cognitive and neuropsychiatric symptoms, but few FDA-approved treatments target disease progression itself.

Key Takeaways:

• The amyloid cascade hypothesis describes the formation and accumulation of β-amyloid (Ab) oligomers and plaques as a primary event in AD pathogenesis.
• Glutaminyl cyclase (QC) catalyzes the cyclization of Ab to form pyroglutamated Ab (pEAb), which acts as the seed for the formation of Ab plaques.
• Inhibiting QC may prevent the formation of pEAb, offering a promising therapeutic strategy against AD.
• The study involves the testing of imidazole-based inhibitor scaffolds and QCI structural optimization via pharmacophore identification.
• Varoglutamstat has entered clinical trials, and further avenues of improving specificity and potency for future QCI development are necessary.
• Emily Boyle, Yana Cen, and Rasajna Madhusudhana were part of the research team at Virginia Commonwealth University.

Statistics:

• 13(6) is the journal issue number in which the study was published.
• 1467 is the article number in Biomedicines.
• The study was financially supported by Nih/nigms; National Center For Advancing Translational Sciences; Cctr Endowment Fund.

Sources:

• An Overview of Glutaminyl Cyclase as a Promising Drug Target for Alzheimer's Disease (Biomedicines - http://www.mdpi.com/journal/biomedicines)
• NewsRx (Reports on Amyloid Findings from Virginia Commonwealth University Provide New Insights (An Overview of Glutaminyl Cyclase as a Promising Drug Target for Alzheimer's Disease). Life Science Weekly. July 8, 2025; p 4359.)